PureTech Health (PRTC) H2 2025 earnings summary

Executive summary

• Refined strategy focuses on operational efficiency, early entity spin-outs, and disciplined capital allocation to maximize shareholder value.

• Hub-and-spoke model leverages external capital for founded entities, retaining significant equity and non-dilutive economics.

• Announced voluntary Nasdaq delisting to streamline structure and reduce costs, maintaining primary LSE listing.

• Four operational pillars: leaner hub, earlier entity launches, innovation focus, and commitment to capital returns.

• Portfolio includes Cobenfy, Seaport, Celea, Gallop, and legacy holdings, with a diversified innovation engine.

Financial highlights

• Ended 2025 with $277.1M in cash equivalents and short-term instruments, down from $366.8M in 2024.

• Unaudited cash and equivalents as of March 31, 2026, were $248.1M at the PureTech level.

• 2025 consolidated revenues were $4.7M, nearly flat year-over-year.

• Operating loss decreased to $98.5M in 2025 from $136.1M in 2024, mainly due to lower G&A and R&D after Seaport deconsolidation.

• Net loss of $110.1M in 2025 versus net income of $27.8M in 2024, reflecting absence of a $151.8M one-time gain from Seaport deconsolidation.

Outlook and guidance

• Operational runway expected at least through end of 2028, inclusive of planned participation in Celea and Gallop fundraisings.

• No inflows from Cobenfy or other monetizations included in runway guidance; any such events represent upside.

• Plans to return a greater proportion of future cash generation to shareholders, especially after outsized returns.

• Expense base expected to further decrease post-Celea spin-out, with ongoing focus on cost discipline.